Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort. Scudeller L, et al. J Antimicrob Chemother. 2003 Nov;52(5):776-81. doi: 10.1093/jac/dkg456. Epub 2003 Oct 16. J Antimicrob Chemother. 2003. PMID: 14563897 Clinical Trial.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
304 results